Movement Alert｜PHARMARON Rises 3.23% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Rally

Market Focus10:04

On August 17, PHARMARON rose 3.23% in regular trading, trading at 30.78 HKD/share, with turnover of approximately 49.52 million HKD.

On the news front, the company's board of directors is scheduled to convene on August 20 to review its first-half interim results. The company previously guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. Notably, new orders signed grew over 30% year-over-year, with small molecule CDMO new orders surging over 50%, underscoring strong earnings visibility ahead of the formal results announcement.

Meanwhile, the broader CXO sector rallied collectively, with GenScript Bio up 5.71%, WuXi AppTec up 4.05%, WuXi Bio up 3.9%, Insilico up 2.47%, and XtalPi up 2.74%, reflecting continued improvement in industry sentiment and ongoing sector valuation recovery driven by robust order momentum across the contract research and manufacturing space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187840468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187840468","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.23% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Rally","media":"Market Focus","content":"<p><p>On August 17, PHARMARON rose 3.23% in regular trading, trading at 30.78 HKD/share, with turnover of approximately 49.52 million HKD.</p><p>On the news front, the company's board of directors is scheduled to convene on August 20 to review its first-half interim results. The company previously guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. Notably, new orders signed grew over 30% year-over-year, with small molecule CDMO new orders surging over 50%, underscoring strong earnings visibility ahead of the formal results announcement.</p><p>Meanwhile, the broader CXO sector rallied collectively, with GenScript Bio up 5.71%, WuXi AppTec up 4.05%, WuXi Bio up 3.9%, Insilico up 2.47%, and XtalPi up 2.74%, reflecting continued improvement in industry sentiment and ongoing sector valuation recovery driven by robust order momentum across the contract research and manufacturing space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.23% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.23% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-17 10:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 17, PHARMARON rose 3.23% in regular trading, trading at 30.78 HKD/share, with turnover of approximately 49.52 million HKD.</p><p>On the news front, the company's board of directors is scheduled to convene on August 20 to review its first-half interim results. The company previously guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. Notably, new orders signed grew over 30% year-over-year, with small molecule CDMO new orders surging over 50%, underscoring strong earnings visibility ahead of the formal results announcement.</p><p>Meanwhile, the broader CXO sector rallied collectively, with GenScript Bio up 5.71%, WuXi AppTec up 4.05%, WuXi Bio up 3.9%, Insilico up 2.47%, and XtalPi up 2.74%, reflecting continued improvement in industry sentiment and ongoing sector valuation recovery driven by robust order momentum across the contract research and manufacturing space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1187840468","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187840468","pubTimestamp":1786932262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 17, PHARMARON rose 3.23% in regular trading, trading at 30.78 HKD/share, with turnover of approximately 49.52 million HKD.On the news front, the company's board of directors is scheduled to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨3.23%，CXO板块上涨中期业绩审查临近","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 17, PHARMARON rose 3.23% in regular trading, trading at 30.78 HKD/share, with turnover of approximately 49.52 million HKD.On the news front, the company's board of directors is scheduled to convene on August 20 to review its first-half interim results. The company previously guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. Notably, new orders signed grew over 30% year-over-year, with small molecule CDMO new orders surging over 50%, underscoring strong earnings visibility ahead of the formal results announcement.Meanwhile, the broader CXO sector rallied collectively, with GenScript Bio up 5.71%, WuXi AppTec up 4.05%, WuXi Bio up 3.9%, Insilico up 2.47%, and XtalPi up 2.74%, reflecting continued improvement in industry sentiment and ongoing sector valuation recovery driven by robust order momentum across the contract research and manufacturing space.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187840468","isCrawlerRequest":true}